APA

Kaowinn S., Jun S. W., Kim C. S., Shin D., Hwang Y., Kim K., Shin B., Kaewpiboon C., Jeong H. H., Koh S. S., Krämer O. H., Johnston R. N. & Chung Y. (20180827). Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. : Cellular oncology (Dordrecht, Netherlands).

Chicago

Kaowinn Sirichat, Jun Seung Won, Kim Chang Seok, Shin Dong-Myeong, Hwang Yoon-Hwae, Kim Kyujung, Shin Bosung, Kaewpiboon Chutima, Jeong Hyeon Hee, Koh Sang Seok, Krämer Oliver H, Johnston Randal N and Chung Young-Hwa. 20180827. Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. : Cellular oncology (Dordrecht, Netherlands).

Harvard

Kaowinn S., Jun S. W., Kim C. S., Shin D., Hwang Y., Kim K., Shin B., Kaewpiboon C., Jeong H. H., Koh S. S., Krämer O. H., Johnston R. N. and Chung Y. (20180827). Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. : Cellular oncology (Dordrecht, Netherlands).

MLA

Kaowinn Sirichat, Jun Seung Won, Kim Chang Seok, Shin Dong-Myeong, Hwang Yoon-Hwae, Kim Kyujung, Shin Bosung, Kaewpiboon Chutima, Jeong Hyeon Hee, Koh Sang Seok, Krämer Oliver H, Johnston Randal N and Chung Young-Hwa. Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. : Cellular oncology (Dordrecht, Netherlands). 20180827.